Lyell Immunopharma (LYEL) Expected to Announce Quarterly Earnings on Wednesday

Lyell Immunopharma (NASDAQ:LYEL) is projected to announce its earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Lyell Immunopharma Trading Up 6.2 %

Shares of LYEL stock opened at $0.70 on Monday. The stock has a market cap of $204.72 million, a P/E ratio of -0.89 and a beta of -0.35. The stock has a 50 day simple moving average of $0.61 and a 200 day simple moving average of $0.99. Lyell Immunopharma has a 1 year low of $0.51 and a 1 year high of $3.26.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on LYEL shares. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, November 12th. Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their price target for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.